Market Place
Sourcing Support
Dupixent Approval For Children With Chronic Spontaneous Urticaria
22 Apr 2026 //
PRESS RELEASE
Sanofi`s Tzield FDA Approved To Delay Stage 3 Type 1 Diabetes
22 Apr 2026 //
PRESS RELEASE
EU Approves Sanofi`s Rezurock for Chronic GVHD Disease
31 Mar 2026 //
PRESS RELEASE
Sanofi’s Venglustat Earns BTD in US for Type 3 Gaucher Disease
18 Mar 2026 //
GLOBENEWSWIRE
Mirecule Expands Strategic FSHD Collaboration With Sanofi
18 Mar 2026 //
PHARMIWEB
Sanofi`s Rilzabrutinib Granted Orphan Drug Status In Japan
03 Mar 2026 //
PRESS RELEASE
DNDi, Sanofi Get CHMP Nod for Single-Dose Sleeping Sickness Tx
27 Feb 2026 //
PRESS RELEASE
Sanofi`s Rilzabrutinib Designated Breakthrough Therapy In US
09 Feb 2026 //
GLOBENEWSWIRE
Sanofi Rare Disease Drug Shows Success And Failure In Phase 3
02 Feb 2026 //
PRESS RELEASE
CHMP Backs Sanofi`s Rezurock for EU Chronic GVHD Approval
31 Jan 2026 //
GLOBENEWSWIRE
EU Approves Sanofi`s Wayrli as First BTK Inhibitor for ITP
23 Dec 2025 //
PRESS RELEASE
Sanofi`s Efdoralprin Alfa Granted EU Orphan Designation
18 Dec 2025 //
PRESS RELEASE
Sanofi’s Qfitlia and Cablivi approved in China
12 Dec 2025 //
PRESS RELEASE
Electra shines with $183M fundraise for rare disease trial
22 Oct 2025 //
GLOBENEWSWIRE
Sanofi`s $1.7B Bet Beats Csl`s Zemaira In Phase 2 Face-Off
22 Oct 2025 //
FIERCE BIOTECH
Sanofi Updates EU Review of Rezurock in Chronic GVHD
17 Oct 2025 //
GLOBENEWSWIRE
Sanofi’s SAR446268 Gets Fast Track for Myotonic Dystrophy Type 1
23 Sep 2025 //
GLOBENEWSWIRE
Sanofi`s Rilzabrutinib Granted EU Orphan Designation
14 Aug 2025 //
PRESS RELEASE
Sanofi’s SAR446523 Gets US Orphan Drug Tag For Multiple Myeloma
31 Jul 2025 //
PRESS RELEASE
Kyowa, Amgen, Sanofi Support Women`s Health Info Update
23 Jul 2025 //
FIERCE PHARMA
Riliprubart Wins Japan Orphan Drug Tag for CIDP Therapy
30 Jun 2025 //
PRESS RELEASE
Riliprubart Earns Orphan Drug Status in Us for Organ Rejection
25 Jun 2025 //
GLOBENEWSWIRE
Dupixent US Approval For Bullous Pemphigoid Treatment
21 Jun 2025 //
PRESS RELEASE
Rilzabrutinib Grants Orphan Designation for Sickle Cell Disease
03 Jun 2025 //
PRESS RELEASE
Sanofi to buy US biopharma group Blueprint for over $9 billion
03 Jun 2025 //
PRESS RELEASE
Rilzabrutinib granted orphan drug designation in US for 2 diseases
04 Apr 2025 //
PRESS RELEASE
Mitem Acquires FLISINT Specialty From Sanofi for Rare Diseases
04 Feb 2025 //
BUSINESSWIRE
Healx Partners with Sanofi to Explore Rare Disease AI Drug Discovery
13 Nov 2024 //
BUSINESSWIRE
Recordati buys rights to rare immune drug from Sanofi for $825 mln
05 Oct 2024 //
REUTERS
Sanofi drops phase 2 dwarfism drug as part of rare disease clear-out
25 Jul 2024 //
FIERCE BIOTECH
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
14 May 2024 //
BIOPHARMADIVE
Rare rheumatology disease in spotlight after Sanofi, Regeneron nab first drug approval
05 Apr 2023 //
ENDPTS
Sanofi reaffirms commitment to rare diseases in India
27 Feb 2023 //
INDIANPHARMAPOST
Sanofi`s rare disease drug Xenpozyme scores FDA approval after nods
01 Sep 2022 //
FIERCEPHARMA
Sanofi`s Paul Hudson scores an FDA OK for a rare disease drug
31 Aug 2022 //
ENDPTS
Sanofi scores a snap review for a rare disease drug, another win
15 May 2020 //
ENDPTS
Drugmakers` oncology, rare diseases rebrands may stay in 2020
19 Dec 2019 //
FIERCE PHARMA
New data to be presented at ASH 2019 highlight Sanofi`s commitment
06 Nov 2019 //
PRESS RELEASE
How Henri Termeer built Genzyme and pioneered the rare disease industry
05 Oct 2019 //
ENDPTS
Amicus rare disease data build hope for approval
03 Oct 2019 //
BIOPHARMADIVE
Sanofi punts 38 R&D projects to narrow pipeline focus
08 Feb 2019 //
FIERCE BIOTECH
FDA approves first therapy for adult patients with rare blood clotting disorder
06 Feb 2019 //
PR NEWSWIRE
NEJM publishes positive detailed results from Praluent® (alirocumab) CV trial
07 Nov 2018 //
GLOBENEWSWIRE
Sanofi Genyzme seeks up to 400,000 square feet in Cambridge
16 Oct 2018 //
BOSTON GLOBE
Sanofi eyes major expansion for Genzyme in Cambridge, MA: report
15 Oct 2018 //
FIERCE PHARMA
Sanofi, Regeneron skin cancer drug gets FDA nod
29 Sep 2018 //
REUTERS
Sanofi reaps first fruit of Ablynx buyout with a European OK
05 Sep 2018 //
ENDPTS
Cablivi™ (caplacizumab) approved in Europe for aTTP
03 Sep 2018 //
PR NEWSWIRE
Amicus sets $315,000 price for new Fabry disease treatment
14 Aug 2018 //
ENDPTS
FDA motions Alnylam’s lumasiran into a PhIII short track, setting up a shot
03 May 2018 //
ENDPTS
Sanofi takes a pass on one rare disease drug, FDA offers ‘breakthrough’ status
12 Mar 2018 //
ENDPTS
Sanofi bets on India with portfolio of drugs for diabetes, rare diseases
13 Feb 2018 //
ECONOMIC TIMES
Sanofi Genzyme to Lay Off 130 Employees at Boston Facility
08 Feb 2018 //
BIOSPACE
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ
23 Jan 2018 //
PMLIVE
After some big setbacks, Sanofi talks up its R&D portfolio
13 Dec 2017 //
PMLIVE
Sanofi, Novo back rare disease startup Inozyme
20 Nov 2017 //
FIERCE BIOTECH
KSQ Emerges With $76 Million and Will be Helmed by Former Genzyme CEO
02 Oct 2017 //
BIOSPACE
Alnylam’s rare disease drug shines in trial, a brand-new class of medicines
20 Sep 2017 //
STATNEWS
Sanofi, Vertex and more back first rare disease film festival
30 Aug 2017 //
FIERCE PHARMA
